Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancer

PUBT · 1d ago
Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancer
  • Guardant Health secured EU CE-marking for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant).
  • Test targets ESR1 mutations in ER-positive, HER2-negative advanced breast cancer to guide treatment selection via blood-based liquid biopsy.
  • Clearance marks Guardant’s 31st companion diagnostic approval, following prior U.S. and Japan authorizations for ETCAMAH.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610081612BIZWIRE_USPR_____20261008_BW669405) on October 08, 2026, and is solely responsible for the information contained therein.